Searchable abstracts of presentations at key conferences in endocrinology

ea0099ep438 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Obesity-related comorbidities as potential factors influencing features of premature ageing in severely obese patients

Dudek Alicja , Zapała Barbara , Ciszek Karol , Kawa Ilona , Zgliczyński Wojciech , Major Piotr

Background: Obesity poses a considerable threat to health, increasing the likelihood of accompanying conditions such as type 2 diabetes, hypertension, dyslipidemia, and cancer. Ageing results in the accumulation of damaging factors leading to the development of chronic diseases. Inflammation levels, telomere length, level of neurocognitive function, metabolic age serve as acknowledged indicators of biological aging. The prevalence of premature ageing in obesity has been eviden...

ea0099ep260 | Endocrine-Related Cancer | ECE2024

Carcinoid heart disease - a single centre experience

Kurzyńska Anna , Stefańska Agnieszka , Kolasa Magdalena , Sowa Staszczak Anna , Hubalewska-Dydejczyk Alicja

Carcinoid heart disease (CHD) affects about 20-50% of patients with carcinoid syndrome (CS) and is the main cause of mortality in this group of patients. The 3-year survival rate in patients with CHD is 31% compared to 68% in those without cardiac involvement. The cause of the development of CHD is the flow of serotonin-rich blood, and the lesions affect the right heart (localizing mainly in the endocardium and inner membrane of large vessels). The study aim was to present a s...

ea0099ep342 | Endocrine-Related Cancer | ECE2024

Heterogeneity of responses of dynamic tests in patients with ectopic cushing’s syndrome (ECS). the half of patients with ECS have an increase in ACTH in the CRH/desmopressin test, nearly 1/3 have complete or some inhibition of cortisol in HDDST

Gamrat Aleksandra , Minasyan Mari , Aleksandra Komisarz-Calik Maria , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: According to the literature, the CRH test has the highest specificity in excluding ECS (ACTH 93.9%, cortisol 89.4%). A combination of the high dose dexamethasone test (HDDST) and CRH/desmopressin test (CRH/desmopressinT) is used to increase the discriminatory capacity in ACTH-dependent CS.Objectives: This study aims to investigate the response to dynamic tests in ECS patients.Methods: 35 consecutive ECS patients were ...

ea0099ep341 | Pituitary and Neuroendocrinology | ECE2024

Volumetric parameters of 68[Ga]Ga-DOTA-TATE PET/CT in the prediction of response to treatment with long-acting somatostatin analogues in patients with well-differentiated NETs

Morawiec-Sławek Karolina , Opalińska Marta , Lenda-Tracz Wioletta , Hubalewska-Dydejczyk Alicja

Introduction: Somatostatin analogues (SSA) are recommended as the first-line systemic therapy, to control tumour growth for advanced or metastatic well-differentiated neuroendocrine tumours (WD NET), with good expression of the somatostatin receptors. [68Ga]Ga-DOTA-SSA PT/CT has become the gold standard in the diagnosis, staging and monitoring therapy, of WD NET.Aim: The aim of the study was to evaluate the predictive role of standardized uptake values (...

ea0099ep352 | Pituitary and Neuroendocrinology | ECE2024

Are giant prolactinomas different from macroprolactinomas? The single-centre observation

Aleksandra Komisarz-Calik Maria , Bogusławska Anna , Gilis-Januszewska Aleksandra , Hubalewska-Dydejczyk Alicja

Introduction: The data on giant prolactinomas (the rare (3%) subtype of lactotroph PitNET (≥40 mm) ), often causing clinical and therapeutic difficulties are scarce.Aim: We studied clinical/biochemical and treatment outcomes differences between giant and macroprolactinomas.Materials and methods: Consecutive patients with giant prolactinomas ≥40 mm (GP) and macroprolactinomas >10 mm<40 mm (MP) treated in the tert...

ea0081rc6.5 | Rapid Communications 6: Endocrine-Related Cancer | ECE2022

Granin family peptides and INSM-1 (Insulinoma-associated protein 1) in the biochemical diagnosis of pheochromocytoma

Glinicki Piotr , Ostrowska Magdalena , Stelmachowska-Banas Maria , Papierska Lucyna , Szatko Alicja , Kowalski Konrad , Zgliczyński Wojciech

Introduction: Pheochromocytoma is a rare, usually benign tumor composed of neuroendocrine (chromaffin) cells of the adrenal medulla. It is the cause of secondary arterial hypertension. The biochemical diagnosis of a pheochromocytoma is based on the determination of concentration/excretion of catecholamine metabolites in blood or urine. The most sensitive biomarkers in the biochemical diagnosis of pheochromocytoma are plasma free methanephrines (metanephrine, normetanephrine an...

ea0081p177 | Pituitary and Neuroendocrinology | ECE2022

Use of corrected SUVmax as a prognostic indicator of response to PRRT

Opalinska Marta , Sowa-Staszczak Anna , Kania-Kuc Adrian , Al Maraih Ibraheem , Gilis-Januszewska Aleksandra , Hubalewska-Dydejczyk Alicja

Background: PRRT is an effective treatment option (especially for controlling disease progression)for disseminated neuroendocrine tumors (NETs), with good expression of the somatostatin receptors. Despite significant progress in NET personalized management, searching for novel predictive and prognostic factors of response to PRRT is crucial for more effective follow-up, better treatment choices leading to more favorable final outcome. Some recent studies indicate that the resp...

ea0081p690 | Pituitary and Neuroendocrinology | ECE2022

Clinical characteristics at diagnosis and diagnostic delay among newly-diagnosed patients with acromegaly- single-center, pilot study

Godlewska Magdalena , Bogusławska Anna , Kluczyński Łukasz , Rzepka Ewelina , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: Diagnostic delay remains significant among the patients with acromegaly, even though the disease awareness has improved over the years.Aim: The aim was to investigate the diagnostic delay and symptoms present at diagnosis of acromegaly among the newly-diagnosed patients.Material and methods: 72 consecutive patients diagnosed with acromegaly between 01.2014 and 12.2021 were evaluated. Division into groups based on: gen...

ea0081p693 | Pituitary and Neuroendocrinology | ECE2022

Multimodal treatment including temozolomide (TMZ) and pasireotide for aggressive, giant silent corticotroph PiTNET in a young patient

Bogusławska Anna , Kluczyński Łukasz , Godlewska Magdalena , Rzepka Ewelina , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Silent corticotroph pituitary neuroendocrine tumours (PiTNETs) are a subtype of nonfunctioning PiTNETs, that present positive immunostaining for adrenocorticotropin (ACTH) and/or show the expression of the transcription factor T-PIT without clinical signs of hypercortisolemia. They constitute 20% of all corticotroph PitNETs and manifest in most cases as macroadenoma with suprasellar extension and a higher tendency to apoplexy. We present a 33-year-old male with aggressive cour...

ea0081p447 | Reproductive and Developmental Endocrinology | ECE2022

Interplay between estrogen signaling and notch pathway in rodent Sertoli cells

Lustofin Sylwia , Kamińska Alicja , Brzoskwinia Małgorzata , Cyran Joanna , Bilińska Barbara , Hejmej Anna

Somatic cells of the seminiferous epithelium, called Sertoli cells, play a key role in germ cell development and maintenance of proper course of spermatogenesis. Although androgens are considered the main regulators of Sertoli cell activity, recent studies indicate that their metabolites, estrogens, also influence Sertoli cell function. Estrogens, act mainly through nuclear estrogen receptors α and β (ERα, ERβ), however non-classical signaling via ...